Left to its own devices, cancer has no trouble pulling the fairly-common arginine out of the bloodstream and fuelling its growth. But when an arginine-inhibiting drug is introduced, the cancer cells have no choice but to turn inwards and consume their internal supply of arginine. The beauty of the technique is that it singles out the sarcoma: since healthy cells produce their own arginine just fine, they remain unaffected by reduced environmental arginine.